Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease

NKF K/DOQI GUIDELINES

K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease

COMPLETE BIBLIOGRAPHY FROM EVIDENCE REPORTS

Abdelhadi M, Nordenstrom J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998 Nov;83(11):3845-3851.

Abitbol C, Chan JC, Trachtman H, Strauss J, Greifer I. Growth in children with moderate renal insufficiency: measurement, evaluation, and treatment. J Pediatr 1996 Aug;129(2):s3-s8.

Abitbol CL, Warady BA, Massie MD, Baluarte HJ, Fleischman LE, Geary DF, Kaiser BA, McEnery PT, Chan JC. Linear growth and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: A report of the Growth Failure in Children with Renal Diseases Study. J Pediatr 1990 Feb;116(2):S46-S54.

Abrams P, Klevmark B. Frequency volume charts: An indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl 1996;179:47-53.

Abugassa S, Nordenstrom J, Eriksson S, Mollerstrom G, Alveryd A. Skeletal remineralization after surgery for primary and secondary hyperparathyroidism. Surgery 1990 Feb;107(2):128-133.

Acchiardo SR, Moore LW, Cockrell S. Does low protein diet halt the progression of renal insufficiency? Clin Nephrol 1986 Jun;25(6):289-294.

Ahn JH, Yoon KS, Lee WI, Suh JT, Lee TW, Ihm CG, Kim MJ. Bone marrow findings before and after treatment with recombinant human erythropoietin in chronic hemodialyzed patients. Clin Nephrol 1995 Mar;43(3):189-195.

Akiba T, Ando R, Kurihara S, Heishi M, Tazawa H, Marumo F. Is the bone mass of hemodialysis patients genetically determined? Kidney Int Suppl 1997 Nov;62:S69-S71.

Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998 Aug;32(2):238-246.

Akizawa T, Kinugasa E, Kitaoka T, Koshikawa S, Nakabayashi N, Watanabe H, Yamawaki N, Kuroda Y. Removal of beta-2-microglobulin by direct hemoperfusion with a newly developed adsorbent. ASAIO Trans 1987 Jul-Sep;33(3):532-537.

Akizawa T, Koshikawa S, Nakazawa R, Yoshida T, Kaneko M, Nitadori Y. Elimination of beta 2-microglobulin by a new polyacrylonitrile membrane dialyser: Mechanism and physiokinetics. Nephrol Dial Transplant 1989;4(5):356-365.

Albertson DA, Poole GV Jr, Myers RT. Subtotal parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism. Am Surg 1985 Jan;51(1):16-20.

Albertucci M, Zielinski CM, Rothberg M, Sterpetti A, Klingman R, Ronk JF. Surgical treatment of the parathyroid gland in patients with end-stage renal disease. Surg Gynecol Obstet 1988 Jul;167(1):49-52.

Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58(1):396-369.

Alexander PT, Schuman ES, Vetto RM, Gross GF, Hayes JF, Standage BA. Repeat parathyroid operation associated with renal disease. Am J Surg 1988 May;155(5):686-689.

Almqvist S, Hjern B, Wasthed B. The diagnostic value of a radioimmunoassay for parathyroid hormone in human serum. Acta Endocrinol (Copenh) 1975 Mar;78(3):493-509.

Alon U, Davidai G, Bentur L, Berant M, Better OS. Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure. Miner Electrolyte Metab 1986;12(5-6):320-325.

Altmann P, Plowman D, Marsh F, Cunningham J. Aluminium chelation therapy in dialysis patients: Evidence for inhibition of haemoglobin synthesis by low levels of aluminium. Lancet 1988 May 7;1(8593):1012-1015.

Ambrosoni P, Heuguerot C, Olaizola I, Acuna G, Fajardo L, Petraglia A, Caorsi H, Lopez J, Kurdian M, Jorgetti V, Aznarez A. Can we use 99mTc-MIBI in functional studies of the parathyroid gland? Nephrol Dial Transplant 1998;13(Suppl 3):33-36.

Ambuhl PM, Meier D, Wolf B, Dydak U, Boesiger P, Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: Impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999 Nov;34(5):875-883.

Ando A, Orita Y, Nakata K, Fukahara Y, Mikami, Jujii M, Nakajima Y, Ueda N, Abe H. The effect of essential amino acid supplementation therapy on prognosis of patients with chronic renal failure estimated on the basis of the markov process. Med J Osaka Univ 1981 Jan 1;32:31-37.

Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987 Mar;9(3):206-210.

Andresen J, Nielsen HE. Osteonecrosis and spontaneous fractures following renal transplantation. A longitudinal study of radiological bone changes and metacarpal bone mass. Acta Orthop Scand 1981 Aug;52(4):397-404.

Andress DL, Hercz G, Kopp JB, Endres DB, Norris KC, Coburn JW, Sherrard DJ. Bone histomorphometry of renal osteodystrophy in diabetic patients. J Bone Miner Res 1987 Dec;2(6):525-531.

Andress DL, Nebeker HG, Ott SM, Endres DB, Alfrey AC, Slatopolsky EA, Coburn JW, Sherrard DJ. Bone histologic response to deferoxamine in aluminum-related bone disease. Kidney Int 1987 Jun;31(6):1344-1350.

Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989 Aug 3;321(5):274-279.

Angeli M, Wong LL, Myers SA, Wong LM, Pasieka JL, Roe MS, Duh QY. Calciphylaxis in patients on hemodialysis: A prevalence study. Surgery 1997;122(6):1083-1090.

Aollin AW, Hart LK. The relationship of health belief motivations, health locus of control and health valuing to dietary compliance of hemodialysis patients. AANNT J 1982 Oct;9(5):41-47.

Ardissino G, Schmitt CP, Bianchi ML, Dacco V, Claris-Appiani A, Mehls O. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. Kidney Int 2000 Sep;58(3):981-988.

Ardissino G, Schmitt CP, Testa S, Claris-Appiani A, Mehls O. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure. Pediatr Nephrol 2000 Jul;14(7):664-668.

Aroldi A, Tarantino A, Montagnino G, Cesana B, Cocucci C, Ponticelli C. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: A prospective study. Transplantation 1997;63(3):380-386.

Arons JA, Collins N, Arons MS. Results of treatment of carpal tunnel syndrome with associated hourglass deformity of the median nerve. J Hand Surg [Am] 1999 Nov;24(6):1192-1195.

Asad SN, Olmer AJ, Letteri JM. Plasma calcium fraction dynamics in uremic patients undergoing hemodialysis. Miner Electrolyte Metab 1984;10(5):333-336.

Asaka M, Iida H, Entani C, Fujita M, Izumino K, Takata M, Seto H, Sasayama S. Total and regional bone mineral density by dual photon absorptiometry in patients on maintenance hemodialysis. Clin Nephrol 1992 Sep;38(3):149-153.

Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999 Feb;33(2):287-293.

Aubia J, Bosch J, Lloveras J, Chine M, Hojman L, Masramon J. Relative hyperphosphaturia in diabetic chronic renal failure: A protective factor of hyperparathyroidism. Miner Electrolyte Metab 1987;13(5):311-315.

Aubia J, Serrano S, Marinoso L, Hojman L, Diez A, Lloveras J, Masramon J. Osteodystrophy of diabetics in chronic dialysis: A histomorphometric study. Calcif Tissue Int 1988 May;42(5):297-301.

Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F. ‘Pulse oral’ versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study [published erratum appears in Nephron 1998 Aug;79(4):509]. Nephron 1997;77(3):267-272.

Bagnis C, Dutto F, Gabella P, Vitale C, D’elia P, Marangella M, Ramello A. Biochemical and hormonal short-term effects of 25-hydroxyvitamin D in patients on continuous peritoneal dialysis. Ital J Miner Electrolyte Metab 1998;12(3-4):73-76.

Bailey GL, Griffiths HJ, Mocelin AJ, Gundy DH, Hampers CL, Merrill JP. Avascular necrosis of the femoral head in patients on chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972;18(0):401-404, 410.

Baker LR, Abrams SM, Roe CJ, Faugere MC, Fanti P, Subayti Y, Malluche HH. Early therapy of renal bone disease with calcitriol: A prospective double-blind study. Kidney Int Suppl 1989 Nov;36(Suppl 27):S140-S142.

Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, Goodwin FJ, Marsh FP, Adami S, Hately W, et al. Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 1986 Oct;26(4):185-191.

Bame SI, Petersen N, Wray NP. Variation in hemodialysis patient compliance according to demographic characteristics. Soc Sci Med 1993 Oct;37(8):1035-1043.

Barata JD, D’Haese PC, Pires C, Lamberts LV, Simoes J, De Broe ME. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996 Jan;11(1):125-132.

Bardin T. Low-dose prednisone in dialysis-related amyloid arthropathy. Rev Rhum Engl Ed 1994;61(9 Suppl):S97-S100.

Bardin T, Kuntz D, Zingraff J, Voisin MC, Zelmar A, Lansaman J. Synovial amyloidosis in patients undergoing long-term hemodialysis. Arthritis Rheum 1985 Sep;28(9):1052-1058.

Bardin T, Lebail-Darne JL, Zingraff J, Laredo JD, Voisin MC, Kreis H, Kuntz D. Dialysis arthropathy: Outcome after renal transplantation . Am J Med 1995 Sep;99(3):243-248.

Bardin T, Zingraff J, Drueke T, Kuntz D. Clinical aspects of beta-2 microglobulin amyloidosis, in Gejyo F, Brancaccio D, Bardin T (eds). Dialysis Amyloidosis. Milan, Italy, Wichtig Editore, 1989, pp 79-90.

Bardin T, Zingraff J, Shirahama T, Noel LH, Droz D, Voisin MC, Drueke T, Dryll A, Skinner M, Cohen AS. Hemodialysis-associated amyloidosis and beta-2 microglobulin. Clinical and immunohistochemical study. Am J Med 1987 Sep;83(3):419-424.

Barrientos A, Arteaga J, Rodicio JL, Alvarez Ude F, Alcazar JM, Ruilope LM. Role of the control of phosphate in the progression of chronic renal failure. Miner Electrolyte Metab 1982 Mar;7(3):127-133.

Barsotti G, Giannoni A, Morelli E, Lazzeri M, Vlamis I, Baldi R, Giovannetti S. The decline of renal function slowed by very low phosphorus intake in chronic renal patients following a low nitrogen diet. Clin Nephrol 1984 Jan;21(1):54-59.

Barsotti G, Guiducci A, Ciardella F, Giovannetti S. Effects on renal function of a low-nitrogen diet supplemented with essential amino acids and ketoanalogues and of hemodialysis and free protein supply in patients with chronic renal failure. Nephron 1981;27(3):113-117.

Barsotti G, Lazzeri M, Cristofano C, Cerri M, Lupetti S, Giovannetti S. The role of metabolic acidosis in causing uremic hyperphosphatemia. Miner Electrolyte Metab 1986;12(2):103-106.

Barsotti G, Lazzeri M, Polloni A, Morelli E, Giovannetti E, Lupetti S, Cupisti A, Dani L, Giovannetti S. Effects of the impairment of renal function and of the pH of gastric secretion on the efficacy of Al(OH)3 to reduce serum inorganic phosphorus. Adv Exp Med Biol 1986;208:493-499.

Barsotti G, Morelli E, Giannoni A, Guiducci A, Lupetti S, Giovannetti S. Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: A controlled trial. Kidney Int Suppl 1983 Dec;16:S278-S284.

Barth RH, Cheigh JS, Sullivan JF, Chami J, Suthanthiran M, Stubenbord WT, Stenzel KH, Rubin AL. The advantage of measurement of intact PTH in the prediction of clinical response and calcium metabolism after subtotal parathyroidectomy for renal osteodystrophy. Trans Am Soc Artif Intern Organs 1983;29:124-128.

Belon C, Dumas R, Tau C, Sabatier R, Bourdeau A, Garabedian M. [Dysregulation of plasma 1,25(OH)2D in calcium restriction in hypercalciuric children]. Arch Fr Pediatr 1992 Jun-Jul;49(6):519-524.

Benz RL, Siegfried JW, Teehan BP. Carpal tunnel syndrome in dialysis patients: Comparison between continuous ambulatory peritoneal dialysis and hemodialysis populations. Am J Kidney Dis 1988 Jun;11(6):473-476.

Bergstrom J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis [letter]. Lancet 1987 Mar 14;1(8533):628-629. [letter]

Berl T, Berns AS, Hufer WE, Hammill K, Alfrey AC, Arnaud CD, Schrier RW. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med 1978 Jun;88(6):774-780.

Berl T, Berns AS, Huffer WE, Alfrey AC, Arnaud CD, Schrier RR. Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis. Contrib Nephrol 1980;18:72-81.

Berlyne GM. Calcium carbonate treatment of uremic acidosis. Isr J Med Sci 1971 Nov;7(11):1235-1239.

Berlyne GM, Hocken AG. Three years experience of a low protein diet in chronic renal failure. The dietary treatment of chronic renal failure, in Berlyne GM (eds): Nutrition in Renal Disease, Proceedings of a Conference Held at The University of Manchester, June 29-30, 1967. Edinburgh, UK, E & S Livingstone Ltd, 1968, pp 38-54.

Bessell JR, Proudman WD, Parkyn RF, Disney AP. Parathyroidectomy in the treatment of patients with chronic renal failure: A 10-year review. Br J Surg 1993 Jan;80(1):40-42.

Better OS, Kleeman CR, Gonick HC, Varrady PD, Maxwell MH. Renal handling of calcium, magnesium and inorganic phosphate in chronic renal failure. Isr J Med Sci 1967 Jan-Feb;3(1):60-79.

Bia MJ, Cooper K, Schnall S, Duffy T, Hendler E, Malluche H, Solomon L. Aluminum induced anemia: Pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 1989 Nov;36(5):852-858.

Bianchi ML, Colantonio G, Montesano A, Trevisan C, Ortolani S, Rossi R, Buccianti G. Bone mass status in different degrees of chronic renal failure. Bone 1992;13(3):225-228.

Billotey C, Sarfati E, Aurengo A, et al. Advantages of SPECT in technetium 99m sestamibi parathyroid scintigraphy. J Nucl Med 1996;37:1773-1778.

Birck R, Zimmermann E, Wassmer S, Nowack R, van der Woude FJ. Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphataemia in patients on maintenance haemodialysis: A cross-over study. Nephrol Dial Transplant 1999 Jun;14(6):1475-1479.

Blackburn SL. Dietary compliance of chronic hemodialysis patients. J Am Diet Assoc 1977 Jan;70(1):31-37.

Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999 Apr;33(4):694-701.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998 Apr;31(4):607-617.

Blocklet D, Martin P, Schoutens A, Verhas M, Hooghe L, Kinnaert P. Presurgical localization of abnormal parathyroid glands using a single injection of technetium-99m methoxyisobutylisonitrile: Comparison of different techniques including factor analysis of dynamic structures. Eur J Nucl Med 1997 Jan;24(1):46-51.

Blodgett CJ. The process of adjustment in chronic renal failure and hemodialysis. Diss Abstr Int 1983;44(3B):905.

Blohme I, Eriksson A. Parathyroidectomy after renal transplantation. Scand J Urol Nephrol Suppl 1977;(42):134-136.

Blumberg A, Burgi W. Behavior of beta 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 1987 May;27(5):245-249.

Bohm R, Gladziwa U, Clasen W, Riehl J, Mann H, Sieberth HG. Which bicarbonate concentration is adequate to lactate-buffered substitution fluids in maintenance hemofiltration? Clin Nephrol 1994 Oct;42(4):257-262.

Bonnin MR, Gonzalez MT, Huguet J, Rosel P, Navarro MA. 1,25-Dihydroxycholecalciferol as measured by a radioreceptor assay in normal subjects and patients after kidney transplantation. Clin Chem 1990 Feb;36(2):389-390.

Bonomini V, Albertazzi A, Bortolotti GC, Vangelista A. Effects of diet, dialysis and transplantation on bone lesions in chronic uraemia. Proc Eur Dial Transplant Assoc 1973;10(0):324-331.

Boran M, Cetin S. Effectiveness of intravenous and subcutaneous calcitriol in the treatment of secondary hyperparathyroidism [letter]. Nephron 1998 Sep;80(1):119-120. [letter]

Boran M, Doruk E, Gonenc F, Cetin S. 125 (OH) cholecalciferol pulse therapy and the effects of different dialysis membranes on serum PTH levels of haemodialysis patients. Int Urol Nephrol 1997;29(2):251-258.

Bouteiller G, Ton That H, Goudable C, Goffinet F, Heche JP, Orfila C, Suc JM. Amyloidosis in chronic hemodialysis: Rheumatological aspects. Contrib Nephrol 1988;62:67-74.

Boyle RM, Chinchilli VM, Shasky DA. Masking of physicians in the Growth Failure in Children with Renal Diseases Clinical Trial. Pediatr Nephrol 1993 Apr;7(2):204-206.

Brady JP, Hasbargen JA. Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. Am J Kidney Dis 1998 Jan;31(1):35-40.

Brandi L, Daugaard H, Egsmose C, Tvedegaard E, Kjaerulff Nielsen P, Olgaard K. Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia. J Intern Med 1996 Apr;239(4):353-360.

Brandi L, Daugaard H, Tvedegaard E, Nielsen PK, Egsmose C, Storm T, Olgaard K. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis. Am J Nephrol 1992;12(5):311-318.

Brandi L, Nielsen PK, Bro S, Daugaard H, Olgaard K. Long-term effects of intermittent oral alfacalcidol, calcium carbonate and low-calcium dialysis (125 mmol L) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis. J Intern Med 1998;244(2):121-131.

Brazil M, Linderer RJ, Dickhans MJ, Garvin PJ. Aseptic hip necrosis after renal transplantation. Arch Surg 1986 Jul;121(7):803-805.

Brezin JH, Schwartz AB, Chinitz JL. Switch from acetate (Ac) to bicarbonate (Bi) dialysis: Better dialysis tolerance but failure to improve acidosis and hypertriglyceridemia (HTG). Trans Am Soc Artif Intern Organs 1985;31:343-348.

Briggs WA, Hampers CL, Merrill JP, Hager EB, Wilson RE, Birtch AG, Murray JE. Aseptic necrosis in the femur after renal transplantation. Ann Surg 1972 Feb;175(2):282-289.

Bro S, Brandi L, Olgaard K. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: Efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone. Nephrol Dial Transplant 1996 Aug;11(8):1586-1591.

Bro S, Brandi L, Olgaard K. Risk/benefit in prophylaxis and treatment of secondary hyperparathyroidism. A comparison of two low calcium peritoneal dialysis fluids. Nephrol Dial Transplant 1996;11 Suppl 3:47-49.

Bro S, Rasmussen RA, Handberg J, Olgaard K, Feldt-Rasmussen B. Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am J Kidney Dis 1998 Feb;31(2):257-262.

Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D’amour P. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000;46(5):697-703.

Brouhard BH, Chan JC, Carter WH Jr. Final report of the Growth Failure in Children with Renal Diseases Study. J Pediatr 1996 Aug;129(2):s1-s3.

Brown EA, Gower PE. Joint problems in patients on maintenance hemodialysis. Clin Nephrol 1982 Nov;18(5):247-250.

Brunner FP, Brynger H, Ehrich JHH, Fassbinder W, Geerlings W, Rizzoni G, Selwood NH, Tufveson G, Wing AJ. Case control study on dialysis arthropathy: The influence of two different dialysis membranes: Data from the EDTA Registry. Nephrol Dial Transplant 1990;5(6):432-436.

Buijsen CG, Struijk DG, Huijgen HJ, Boeschoten EW, Wilmink JM. Can low-calcium peritoneal dialysis solution safely replace the standard calcium solution in the majority of chronic peritoneal dialysis patients? Perit Dial Int 1996 Sep-Oct;16(5):497-504.

Caglar M, Adeera L. Factors affecting bone mineral density in renal transplant patients. Ann Nucl Med 1999 Jun;13(3):141-145.

Calenoff L, Norfray J. Magnification digital roentgenography: A method for evaluating renal osteodystrophy in hemodialyzed patients. Am J Roentgenol Radium Ther Nucl Med 1973 Jun;118(2):282-292.

Campistol JM, Ponz E, Munoz-Gomez J, Oppenheimer F, Ricard MJ, Vilardell J, Andreu J. Renal transplantation for dialysis amyloidosis. Transplant Proc 1992 Feb;24(1):118-119.

Campos C, Arata RO, Mautalen CA. Parathyroid hormone and vertebral osteosclerosis in uremic patients. Metabolism 1976 May;25(5):495-501.

Canavese C, Barolo S, Gurioli L, Cadario A, Portigliatti M, Isaia G, Thea A, Marangella M, Bongiorno P, Cavagnino A, Peona C, Boero R, D’amicone M, Cardelli R, Rossi P, Piccoli G. Correlations between bone histopathology and serum biochemistry in uremic patients on chronic hemodialysis. Int J Artif Organs 1998;21(8):443-450.

Canteros A, Diaz-Corte C, Fernandez-Martin JL, Gago E, Fernandez-Merayo C, Cannata J. Ultrafiltrable aluminium after very low doses of desferrioxamine. Nephrol Dial Transplant 1998 Jun;13(6):1538-1542.

Caravaca F, Cubero JJ, Jimenez F, Lopez JM, Aparicio A, Cid MC, Pizarro JL, Liso J, Santos I. Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uraemic patients with secondary hyperparathyroidism. Nephrol Dial Transplant 1995;10(5):665-670.

Caravaca F, Fernandez MA, Ruiz-Calero R, Cubero J, Aparicio A, Jimenez F, Garcia MC. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 1998;13(10):2605-2611.

Caravaca F, Santos I, Cubero JJ, Esparrago JF, Arrobas M, Pizarro JL, Robles R, Sanchez-Casado E. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 1992;60(4):423-427.

Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000 Jul;36(1):160-166.

Cassidy MJ, Owen JP, Ellis HA, Dewar J, Robinson CJ, Wilkinson R, Ward MK, Kerr DN. Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J M 1985 Jan;54(213):29-48.

Catizone L, Cocchi R, Fusaroli M, Zucchelli P. Relationship between plasma ß2-microglobulin and residual diuresis in continuous ambulatory peritoneal dialysis and hemodialysis patients. Perit Dial Int 1993;13(Suppl 2):S523-S526.

Chan JC, Kodroff MB, Landwehr DM. Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure. Pediatrics 1981 Oct;68(4):559-571.

Chan JC, McEnery PT, Chinchilli VM, Abitbol CL, Boineau FG, Friedman AL, Lum GM, Roy S 3rd, Ruley EJ, Strife CF. A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus dihydrotachysterol. The Growth Failure in Children with Renal Diseases Investigators. J Pediatr 1994 Apr;124(4):520-528.

Chan R, Gleim GW, DeVita MV, Zabetakis PM, Michelis MF. Effects of oral vs. intravenous calcitriol on serum parathyroid hormone levels in chronic hemodialysis. Dial Transplant 1993;22:736-739.

Chan YL, Furlong TJ, Cornish CJ, Posen S. Dialysis osteodystrophy. A study involving 94 patients. Medicine 1985;64(5):296-309.

Chanard J, Bindi P, Lavaud S, Toupance O, Maheut H, Lacour F. Carpal tunnel syndrome and type of dialysis membrane. BMJ 1989 Apr 1;298(6677):867-868.

Chandran PK, Ulahannan TJ, Skiles M. Biochemical changes following parathyroidectomy. Int J Artif Organs 1993 Oct;16(10):700-703.

Channon SM, Arfeen S, Ward MK. Long-term accumulation of aluminum in patients with renal failure. Trace Elem Med 1988;5(4):154-157.

Chappuis P, de Vernejoul MC, Paolaggi F, Rousselet F. Relationship between hair, serum and bone aluminium in hemodialyzed patients. Clin Chim Acta 1989 Feb 22;179(3):271-278.

Charhon S, Yafi SE, Gaillard M, Beruard M, Janin G, Accominotti M, Traeger J, Meunier PJ. Deferoxamine for the diagnosis and treatment of aluminum-associated osteodystrophy. Contrib Nephrol 1988;64:160-169.

Charhon SA, Chavassieux P, Boivin G, Parisien M, Chapuy MC, Traeger J, Meunier PJ. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study. Clin Sci 1987 Aug;73(2):227-234.

Charhon SA, Chavassieux PM, Meunier PJ, Accominotti M. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis. Br Med J (Clin Res Ed) 1985 Jun 1;290(6482):1613-1614.

Charhon SA, Delmas PD, Malaval L, Chavassieux PM, Arlot M, Chapuy MC, Meunier PJ. Serum bone Gla-protein in renal osteodystrophy: Comparison with bone histomorphometry. J Clin Endocrinol Metab 1986 Oct;63(4):892-897.

Charhon SA, Delmas PD, Malaval L, Chavassieux PM, Chapuy MC, Meunier PJ. Serum bone gla-protein compared to bone histomorphometry in hemodialyzed patients. Adv Exp Med Biol 1986;208:291-296.

Charra B, Calemard E, Laurent G. Chronic renal failure treatment duration and mode: Their relevance to the late dialysis periarticular syndrome. Blood Purif 1988;6(2):117-124.

Chattopadhyay C, Ackrill P, Clague RB. The shoulder pain syndrome and soft-tissue abnormalities in patients on long-term haemodialysis. Br J Rheumatol 1987 Jun;26(3):181-187.

Chauveau P, Poignet JL, Kuno T, Bonete R, Kerembrun A, Naret C, Delons S, Man NK, Rist E. Phosphate removal rate: A comparative study of five high-flux dialysers. Nephrol Dial Transplant 1991;6 Suppl 2:114-115.

Chazan JA, Libbey NP, London MR, Pono L, Abuelo JG. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: A correlation between biochemical parameters and bone pathology findings. Clin Nephrol 1991;35(2):78-85.

Chazot C, Chazot I, Charra B, Terrat JC, Vanel T, Calemard E, Ruffet M, Laurent G. Functional study of hands among patients dialysed for more than 10 years. Nephrol Dial Transplant 1993;8(4):347-351.

Cheng IK, Lu HB, Chan CY, Cheng SW, Robinson JD, Tam SC, Lo WK, Cheung WC. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder. Clin Nephrol 1993 Aug;40(2):100-105.

Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E. Poly [allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997 Jan;29(1):66-71.

Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999 Jan;51(1):18-26.

Chertow GM, Dillon MA, Amin N, Burke SK. Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. J Ren Nutr 2000 Jul;10(3):125-132.

Chertow GM, Trimbur T, Karlson EW, Lazarus JM, Kay J. Performance characteristics of a dialysis-related amyloidosis questionnaire. J Am Soc Nephrol 1996 Aug;7(8):1235-1240.

Chesney RW, Hamstra AJ, Mazess RB, Rose P, DeLuca HF. Circulating vitamin D metabolite concentrations in childhood renal diseases. Kidney Int 1982 Jan;21(1):65-69.

Chesney RW, Hamstra AJ, Phelps M, DeLuca HF. Vitamin D metabolites in renal insufficiency and other vitamin D disorders of children. Kidney Int Suppl 1983 Nov;15:S63-S69.

Chesser AM, Carroll MC, Lightowler C, Macdougall IC, Britton KE, Baker LR. Technetium-99m methoxy isobutyl isonitrile (MIBI) imaging of the parathyroid glands in patients with renal failure. Nephrol Dial Transplant 1997 Jan;12(1):97-100.

Cheung AK, Manolagas SC, Catherwood BD, Mosely CA Jr, Mitas JA 2d, Blantz RC, Deftos LJ. Determinants of serum 1,25(OH)2D levels in renal disease. Kidney Int 1983 Jul;24(1):104-109.

Chinchilli VM, McEnery PT, Chan JC. Statistical methods and determination of sample size in the Growth Failure in Children with Renal Diseases Study. J Pediatr 1990 Feb;116(2):S32-S36.

Cho YL, Liu HN, Huang TP, Tarng DC. Uremic pruritus: Roles of parathyroid hormone and substance P . J Am Acad Dermatol 1997 Apr;36(4):538-543.

Chou FF, Chan HM, Huang TJ, Lee CH, Hsu KT. Autotransplantation of parathyroid glands into subcutaneous forearm tissue for renal hyperparathyroidism. Surgery 1998 Jul;124(1):1-5.

Chou FF, Lee CH, Lee CT. Muscle force and bone mineral density after parathyroidectomy and subcutaneous autotransplantation for secondary hyperparathyroidism. World J Surg 1999 May;23(5):452-456; 456-457.

Christensen AJ, Smith TW. Personality and patient adherence: Correlates of the five-factor model in renal dialysis. J Behav Med 1995 Jun;18(3):305-313.

Christiansen C. Chronic renal failure and vitamin D metabolites: A status report. J Steroid Biochem 1983 Jul;19(1B):517-523.

Christiansen C, Christensen MS, Hartnack B, Melsen F, Transbol I, Rodbro P. Vitamin-D analogues and renal function [letter]. Lancet 1979 Jan 6;1(8106):50-51.

Christiansen C, Christensen MS, Melsen F, Rodbro P, DeLuca HF. Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D. Clin Nephrol 1981 Jan;15(1):18-22.

Christiansen C, Rodbro P, Christensen MS, Hartnack B. Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure? Clin Endocrinol (Oxf) 1981 Sep;15(3):229-236.

Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 1978 Sep 30;2(8092 Pt 1):700-703.

Christiansen C, Rodbro P, Christensen MS, Naestoft J, Hartnack B, Transbool I. Decreased renal function in association with administration of 1,25- dihydroxyvitamin D3 to patients with stable, advanced renal failure. Contrib Nephrol 1980;18:139-146.

Chudek J, Karkoszka H, Schmidt-Gayk H, Ritz E, Kokot F. Plasma parathyroid hormone, phosphatemia and vitamin D receptor genotype: Are they interrelated? J Nephrol 2000 Jan-Feb;13(1):54-58.

Chylkova V, Fixa P, Rozprimova L, Palicka V, Hartmann M, Erben J, Prochazkova J. Beta-2-microglobulin in patients with renal disease. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 1988

Cianciaruso B, Capuano A, D’Amaro E, Ferrara N, Nastasi A, Conte G, Bellizzi V, Andreucci VE. Dietary compliance to a low protein and phosphate diet in patients with chronic renal failure. Kidney Int Suppl 1989 Nov;27:S173-S176.

Claeyssens S, Lavoinne A, Daragon A, Josse S, Godin M, Matray F, Kuhn JM. Total and ultrafiltrable plasma magnesium in hyper- and hypoparathyroidism, and in calcium-related metabolic disorders. Clin Chim Acta 1991 Jan 15;195(3):107-114.

Clark AG, Oner A, Ward G, Turner C, Rigden SP, Haycock GB, Chantler C. Safety and efficacy of calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant 1989;4(6):539-544.

Clark AG, Oner A, Ward G, Turner C, Rigden SPA, Haycock GB, Chantler C. Safety and efficacy or calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant 1989;4(6):539-544.

Clark HO, Stark DA, Duh YQ, Arnaud DC, Gooding AW. Value of high resolution real-time ultrasonography in secondary hyperparathyroidism. Am J Surg 1985 Jul;150(1):9-17.

Clase CM, Norman GL, Beecroft ML, Churchill DN. Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant 2000 Nov;15(11):1841-1846.

Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm 1995 Sep 1;52(17):1895-1900.

Coburn JW. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 1990;38:554-561.

Coburn JW, Norris KC. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine. Semin Nephrol 1986 Dec;6(4 Suppl 1):12-21.

Cochran M, Bulusu L, Horsman A, Stasiak L, Nordin BE. Hypocalcaemia and bone disease in renal failure. Nephron 1973;10(2):113-140.

Cochrane methods working group on systematic review of screening and diagnostic tests: Recommended methods [book online]. Bedford Park (Australia): The Cochrane Collaboration, Australasian Cochrane Centre; 1996 Jun 6 [cited 1999 Jan 07]. [12p]. Available: http://som.flinders.edu.au/fusa/cochrane/.

Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000 Dec;36(6):1115-1121.

Coen G, Mazzaferro S, Ballanti P, Bonucci E, Bondatti F, Manni M, Pasquali M, Perruzza I, Sardella D, Spurio A. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol 1992;12(4):246-251.

Coen G, Mazzaferro S, Ballanti P, Bonucci E, Cinotti GA, Fondi G, Manni M, Pasquali M, Perruzza I, Sardella D, et al. Two-site immunoradiometric intact parathyroid hormone assay versus C-terminal parathyroid hormone in predicting osteodystrophic bone lesions in predialysis chronic renal failure. J Lab Clin Med 1993 Jul;122(1):103-109.

Coen G, Mazzaferro S, Ballanti P, Costantini S, Bonucci E, Bondatti F, Manni M, Pasquali M, Sardella D, Taggi F. Treatment with 1,25(QH)2D3 in predialysis chronic renal failure. Contrib Nephrol 1991;90:183-188.

Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 1996;11(5):813-819.

Coen G, Mazzaferro S, Bonucci E, Ballanti P, Massimetti C, Donato G, Landi A, Smacchi A, Della Rocca C, Cinotti GA, et al. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1,25(OH)2D3: humoral and histomorphometric results. Miner Electrolyte Metab 1986;12(5-6):375-382.

Coen G, Mazzaferro S, Bonucci E, Taggi F, Ballanti P, Bianchi AR, Donato G, Massimetti C, Smacchi A, Cinotti GA. Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up. Kidney Int 1985 Nov;28(5):783-790.

Coen G, Mazzaferro S, Costantini S, Ballanti P, Carrieri MP, Giordano R, Smacchi A, Sardella D, Bonucci E, Taggi F. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment. Miner Electrolyte Metab 1989;15(5):295-302.

Coen G, Mazzaferro S, Manni M, Napoletano I, Fondi G, Sardella D, Perruzza I, Pasquali M, Taggi F. Treatment with small doses of 1,25-dihydroxyvitamin D in predialysis chronic renal failure may lower the rate of decline of renal function. Ital J Miner Electrolyte Metab 1994;8(3):117-121.

Coggins CH, Dwyer JT, Greene T, Petot P, Snetselaar LG, Van Lente F, Striker GE, Sandberg AM, Hirschman GH, Anderson A, Edington B, Norwood E. Serum lipid changes associated with modified protein diets: Results from the feasibility phase of the modification of diet in renal disease study. Am J Kidney Dis 1994;23(4):514-523.

Cohen ME, Cohen GF, Ahad V, Kaye M. Renal osteodystrophy in patients on chronic haemodialysis. A radiological study. Clin Radiol 1970 Apr;21(2):124-134.

Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med 1989 Apr;8(4):441-454.

Coles GA, Gokal R, Ogg G, Jani F, O’Donoghue DT, Cancarinu GC, Maiorca R, Tranaeus A, Faict D, De Vos C. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 1997;17(1):48-51.

Combe C, Deforges-Lasseur C, Caix J, Pommereau A, Marot D, Aparicio M. Compliance and effects of nutritional treatment on progression and metabolic disorders of chronic renal failure. Nephrol Dial Transplant 1993;8(5):412-418.

Combe C, Morel D, de Precigout V, Blanchetier V, Bouchet JL, Potaux L, Fournier A, Aparicio M. Long-term control of hyperparathyroidism in advanced renal failure by low-phosphorus low-protein diet supplemented with calcium (without changes in plasma calcitriol). Nephron 1995;70(3):287-295.

Conceicao SC, Weightman D, Smith PA, Luno J, Ward MK, Kerr DN. Serum ionised calcium concentration: measurement versus calculation. Br Med J 1978 Apr 29;1(6120):1103-1105.

Conger JD, Hammond WS, Alfrey AC, Contiguglia SR, Stanford RE, Huffer WE. Pulmonary calcification in chronic dialysis patients. Clinical and pathologic studies. Ann Intern Med 1975 Sep;83(3):330-336.

Cook TD, Campbell DT. Quasi-Experimentation design & analysis issues for field settings. Boston, MA, Houghton Mifflin Company, 1979. Quasi-experiments: nonequivalent control group designs. pp 95-146.

Copley JB, Hui SL, Leapman S, Slemenda CW, Johnston CC Jr. Longitudinal study of bone mass in end-stage renal disease patients: effects of parathyroidectomy for renal osteodystrophy. J Bone Miner Res 1993 Apr;8(4):415-422.

Coronel F, Lozano C, Herrero JA, Horcajo P, Marron B, Barrientos A. A prospective longitudinal study of bone densitometry in patients starting peritoneal dialysis. Perit Dial Int 1997;17(1):80-82.

Costantini S, Giordano R, Vernillo I, Piccioni A, Zapponi GA. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients. Ann Ist Super Sanita 1989;25(3):457-461.

Couttenye MM, D’haese PC, Deng JT, Van Hoof VO, Verpooten GA, De Broe ME. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 1997;12(10):2144-2150.

Couttenye MM, D’haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, De Broe ME. Low serum levels of alkaline phosphatase of bone origin: A good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996;11(6):1065-1072.

Coyne T, Olson M, Bradham K, Garcon M, Gregory P, Scherch L. Dietary satisfaction correlated with adherence in the Modification of Diet in Renal Disease Study. J Am Diet Assoc 1995 Nov;95(11):1301-1306.

Langman C. (Children’s Memorial Hospital, Chicago, IL). Personal communication. December 22, 2000.

Cueto-Manzano AM, Konel S, Freemont AJ, Adams JE, Mawer B, Gokal R, Hutchison AJ. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am J Kidney Dis 2000 Feb;35(2):227-236.

Cueto-Manzano AM, Konel S, Hutchison AJ, Crowley V, France MW, Freemont AJ, Adams JE, Mawer B, Gokal R. Bone loss in long-term renal transplantation: Histopathology and densitometry analysis. Kidney Int 1999 May;55(5):2021-2029.

Cummings KM, Becker MH, Kirscht JP, Levin NW. Psychosocial factors affecting adherence to medical regiments in a group of hemodialysis patients. Med Care 1982 Jun;20(6):567-580.

Cundy T, Bartlett M, Bishop M, Earnshaw M, Smith R, Kanis JA. Plasma hydroxyproline in uremia: Relationships with histologic and biological indices of bone turnover. Metab Bone Dis Relat Res 1983;4(5):297-303.

Cundy T, Hand DJ, Oliver DO, Woods CG, Wright FW, Kanis JA. Who gets renal bone disease before beginning dialysis? Br Med J (Clin Res Ed) 1985 Jan 26;290(6464):271-275.

Cushner HM, Copley JB, Lindberg JS, Foulks CJ. Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF [published erratum appears in Kidney Int 1988 May;33(5):1047]. Kidney Int 1988 Jan;33(1):95-99.

D’Alessandro AM, Melzer JS, Pirsch JD, Sollinger H-W, Kalayoglu M, Vernon WB, Belzer FO, Starling JR. Tertiary hyperparathyroidism after renal transplantation: Operative indications. Surgery 1989;106(6):1049-1056.

D’Alessandro AM, Melzer JS, Pirsch JD, Sollinger HW, Kalayoglu M, Vernon WB, Belzer FO, Starling JR. Tertiary hyperparathyroidism after renal transplantation: Operative indications. Surgery 1989 Dec;106(6):1049-55; discussion 1055-.

D’Amico G, Gentile MG, Fellin G, Manna G, Cofano F. Effect of dietary protein restriction on the progression of renal failure: A prospective randomized trial. Nephrol Dial Transplant 1994;9(11):1590-1594.

D’Haese PC, Clement JP, Elseviers MM, Lamberts LV, Van de Vyver FL, Visser WJ, De Broe ME. Value of serum aluminium monitoring in dialysis patients: A multicentre study. Nephrol Dial Transplant 1990;5(1):45-53.

D’Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, Fagalde A, Barsoum RS, Lamberts LV, De Broe ME. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 1995 Oct;10(10):1874-1884.

Dahl E, Nordal KP, Aksnes L, Halse J. Bone remodeling in predialysis chronic renal failure: How does the choice of index for mineralizing surface influence the interpretation? J Bone Miner Res 1989 Dec;4(6):845-852.

Dahl E, Nordal KP, Attramadal A, Halse J, Flatmark A. Renal osteodystrophy in predialysis patients without stainable bone aluminium. A cross-sectional bone-histomorphometric study. Acta Med Scand 1988;224(2):157-164.

Dahl E, Nordal KP, Attramadal A, Halse J, Flatmark A. Renal osteodystrophy in predialysis patients without stainable bone aluminum. A cross-sectional bone-histomorphometric study. Acta Med Scand 1988;224(2):157-164.

Dahl E, Nordal KP, Halse J, Flatmark A. Pretransplant parathyroidectomy in renal failure: Effects on bone histology and aluminum deposits during dialysis and after kidney transplantation. Scand J Urol Nephrol 1992;26(3):283-288.

Dalal S, Yu AW, Gupta DK, Kar PM, Ing TS, Daugirdas JT. L-lactate high-efficiency hemodialysis: Hemodynamics, blood gas changes, potassium/phosphorus, and symptoms. Kidney Int 1990 Nov;38(5):896-903.

Dalal SP, Ajam M, Gupta DK, Gupta R, Nawab Z, Manahan FJ, Ing TS, Daugirdas JT. L-lactate for high-efficiency hemodialysis: Feasibility studies and a randomized comparison with acetate and bicarbonate. Int J Artif Organs 1989 Oct;12(10):611-617.

Dalen N, Alvestrand A. Bone mineral content in chronic renal failure and after renal transplantation. Clin Nephrol 1973 Nov-Dec;1(6):338-346.

Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol 1993;27(4):447-451.

Davidson JK, Tsakiris D, Briggs JD, Junor BJ. Osteonecrosis and fractures following renal transplantation. Clin Radiol 1985 Jan;36(1):27-35.

Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986 May-Jun;1(3):155-158.

Davison AM, Peacock M, Walker GS, Marshall DH, McLaughlin MS, Robinson PJ. Phosphate and 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients. Clin Endocrinol (Oxf) 1977 Dec;7 Suppl:91s-99s.

Dawborn JK, Brown DJ, Douglas MC, Eddey HH, Heale WF, Thomas DP, Xipell JM. Parathyroidectomy in chronic renal failure. Nephron 1983;33(2):100-105.

De Francisco AM, Cassidy MJ, Owen JP, Ellis HA, Farndon JR, Ward MK, Kerr DN. Ectopic calcification. The role of parathyroid hormone. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:888-894.

de Francisco AM, Ellis HA, Owen JP, Cassidy MJ, Farndon JR, Ward MK, Kerr DN. Parathyroidectomy in chronic renal failure. Q J M 1985 Jun;55(218):289-315.

de Francisco AM, Riancho JA, Amado JA, del Arco C, Macias JG, Cotorruelo JG, Arias M. Calcium, hyperparathyroidism, and vitamin D metabolism after kidney transplantation. Transplant Proc 1987 Oct;19(5):3721-3723.

de Graaf P, Pauwels EK, Vos PH, Schicht IM, te Velde J, de Graeff J. Observations on computerized quantitative bone scintigraphy in renal osteodystrophy. Eur J Nucl Med 1984;9(9):419-425.

de Graaf P, te Velde J, Pauwels EK, Schicht IM, Kleiverda K, de Graeff J. Increased bone radiotracer uptake in renal osteodystrophy. Clinical evidence of hyperparathyroidism as the major cause. Eur J Nucl Med 1982;7(4):152-154.

De Graaf P, Van Hooff JP, Boekhout M, Achterberg J, Pauwels EK, Kalff MW. Hyperparathyroidism and avascular necrosis of bone after kidney transplantation. A retrospective study of 170 transplant recipients. Neth J Med 1982;25(7):230-236.

De Vecchi A, Rivolta E, Tarantino A, Egidi F, Berardinelli L, Vegeto A, Ponticelli C. Controlled trial of two different methylprednisolone doses in cadaveric renal transplantation. Nephron 1985;41(3):262-266.

de Vernejoul MC, Marchais S, London G, Bielakoff J, Chappuis P, Morieux C, Llach F. Deferoxamine test and bone disease in dialysis patients with mild aluminum accumulation. Am J Kidney Dis 1989 Aug;14(2):124-130.

de Vernejoul MC, Marchais S, London G, Morieux C, Bielakoff J, Miravet L. Increased bone aluminum deposition after subtotal parathyroidectomy in dialyzed patients. Kidney Int 1985 May;27(5):785-791.

Deicher R, Exner M, Cohen G, Haag-Weber M, Horl WH. Neutrophil beta(2)-microglobulin and lactoferrin content in renal failure patients. Am J Kidney Dis 2000 Jun;35(6):1117-1126.

Delling G, Luhmann H, Bulla M, Fuchs C, Henning HV, Jansen JL, Kohnle W, Schulz W. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure. Contrib Nephrol 1980;18:105-121.

Delmez JA, Fallon MD, Harter HR, Hruska KA, Slatopolsky E, Teitelbaum SL. Does strict phosphorus control precipitate renal osteomalacia? J Clin Endocrinol Metab 1986 Apr;62(4):747-752.

Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 1996 Jan;49(1):163-167.

Delmonico FL, Wang CA, Rubin NT, Fang LS, Herrin JT, Cosimi AB. Parathyroid surgery in patients with renal failure. Ann Surg 1984 Nov;200(5):644-647.

Demeure MJ, Ugee DC, Wilkes W, Duh QY, Clark OH. Results of surgical treatment for hyperparathyroidism associated with renal disease. Am J Surg 1990 Oct;160(4):337-340.

Denney JD, Sherrard DJ, Nelp WB, Chesnut CH 3d, Baylink DJ. Total body calcium and long-term calcium balance in chronic renal disease. J Lab Clin Med 1973 Aug;82(2):226-240.

DeVeber GA, Oreopoulos DG, Rabinovich S, Lloyd GJ, Meema HE, Beattie BL, Levy D, Husdan H, Rapoport A. Changing pattern of renal osteodystrophy with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1970;16:479-485.

DeVita MV, Rasenas LL, Bansal M, Gleim GW, Zabetakis PM, Gardenswartz MH, Michelis MF. Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore) 1992 Sep;71(5):284-290.

Diethelm AG, Adams PL, Murad TM, Daniel WW, Whelchel JD, Rutsky EA, Rostand SG. Treatment of secondary hyperparathyroidism in patients with chronic renal failure by total parathyroidectomy and parathyroid autograft. Ann Surg 1981 Jun;193(6):777-793.

DiRaimondo CR, Pollak VE. Beta 2-microglobulin kinetics in maintenance hemodialysis: A comparison of conventional and high-flux dialyzers and the effects of dialyzer reuse. Am J Kidney Dis 1989 May;13(5):390-395.

Djukanovic L, Pejanovic S, Dragojlovic Z, Stosovic M. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3. Ren Fail 1994 Nov;16(6):715-723.

Donckier V, Decoster-Gervy C, Kinnaert P. Long-term results after surgical treatment of renal hyperparathyroidism when fewer than four glands are identified at operation. J Am Coll Surg 1997 Jan;184(1):70-74.

Douthat WG, Acuna Aguerre G, Fernandez Martin JL, Mouzo R, Cannata Andia JB. Treatment of aluminium intoxication: A new scheme for desferrioxamine administration. Nephrol Dial Transplant 1994;9(10):1431-1434.

Douthat WG, Aguerre GA, Martin JLF, Mouzo R, Cannata Andia JB. Treatment of aluminium intoxication: A new scheme for desferrioxamine administration. Nephrol Dial Transplant 1994;9(10):1431-1434.

Coburn J. (UCLA, Dept. of Nephrology, Los Angeles, CA). Personal communication. January 31, 2001.

Drueke T, Fauchet M, Fleury J, Lesourd P, Toure Y, Le Pailleur C, de Vernejoul P, Crosnier J. Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet 1980 Jan 19;1(8160):112-114.

Drusano GL, Standiford HC, Bustamante CJ, et al. Safety and tolerability of multiple doses of imipenem/cilastatin. Clin Pharmacol Ther 1985;37(5):539-543.

Dubost C, Kracht M, Assens P, Sarfati E, Zingraff J, Drueke T. Reoperation for secondary hyperparathyroidism in hemodialysis patients. World J Surg 1986 Aug;10(4):654-660.

Duffy P, Picker RH, Duffield S, Reeve T, Hewlett S. Parathyroid sonography: A useful aid to preoperative localization. J Clin Ultrasound 1980 Apr;8(2):113-116.

Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ. Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 1993 Feb;16(2):483-492.

Dumoulin G, Hory B, Nguyen NU, Henriet MT, Bresson C, Regnard J, Saint-Hillier Y. Lack of evidence that cyclosporine treatment impairs calcium-phosphorus homeostasis and bone remodeling in normocalcemic long-term renal transplant recipients. Transplantation 1995 Jun 27;59(12):1690-1694.

Dunstan CR, Hills E, Norman AW, et al. Treatment of hemodialysis bone disease with 24,25-(OH)D and 1,25-(OH)D alone or in combination. Miner Electrolyte Metab 1985;11(6):358-368.

Duursma SA, Visser WJ, Mees EJ, Njio L. Serum calcium, phosphate and alkaline phosphatase and morphometric bone examinations in 30 patients with renal insufficiency. Calcif Tissue Res 1974;16(2):129-138.

Duursma SA, Visser WJ, Njio L. A quantitative histological study of bone in 30 patients with renal insufficiency. Calcif Tissue Res 1972;9(3):216-225.

Duursma SA, Visser WJ, Raymakers JA, Hart W. A comparative study of radiological and morphometric determinations of bone density in patients with renal osteodystrophy. Folia Med Neerl 1972;15(6):267-270.

Eastwood JB. Quantitative bone histology in 38 patients with advanced renal failure. J Clin Pathol 1982 Feb;35(2):125-134.

Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study [published erratum appears in J Am Soc Nephrol 1997 Mar;8(3):493]. J Am Soc Nephrol 1996 Dec;7(12):2616-2626.

Ei I, Maruyama H, Gejyo F, Okada M, Aoyagi R, Sato T, Ohara K, Tanizawa T, Takahashi HE, Arakawa M. Histomorphometric analysis of aplastic bone disease in chronic renal failure at initiation of haemodialysis: Relation to aluminum and parathormone. Nephrology 1998;4(3):129-136.

Eke FU, Winterborn MH, Robertson PW. Detection of early renal osteodystrophy. Child Nephrol Urol 1988-89;9(1-2):33-37.

el-Reshaid K, el-Reshaid W, Sugathan T, al-Mohannadi S, Sivanandan R. Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 1997;17(6):505-510.

Ellis HA, Peart KM. Azotaemic renal osteodystrophy: A quantitative study on iliac bone. J Clin Pathol 1973 Feb;26(2):83-101.

Elmstedt E. Avascular bone necrosis in the renal transplant patient: A discriminant analysis of 144 cases. Clin Orthop 1981 Jul-Aug;(158):149-157.

Elmstedt E. Incidence of skeletal complications in renal graft recipients. Effect of changes in pharmacotherapy. Acta Orthop Scand 1982 Dec;53(6):853-856.

Elvin A. Therapy evaluation and diagnostic accuracy in neuroendocrine tumours: Assessment of radiological methods. Acta Radiol Suppl 1993;390:1-25.

Emiliani G, Riegler P, Corradini R, Huber W, Fusaroli M. Calcium-phosphorus metabolism after successful kidney transplantation: comparison between patients treated with conventional immunosuppressive therapy and cyclosporin A. Dev Toxicol Environ Sci 1986;14:157-162.

Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991 May;17(5):544-550.

Escobedo EM, Hunter JC, Zink-Brody GC, Andress DL. Magnetic resonance imaging of dialysis-related amyloidosis of the shoulder and hip. Skeletal Radiol 1996 Jan;25(1):41-48.

Esselstyn CB Jr, Popowniak KL. Parathyroid surgery in the treatment of renal osteodystrophy and tertiary hyperparathyroidism. Surg Clin North Am 1971 Oct;51(5):1211-1217.

Abbott Laboratories. Essentials in osteo dynamics manual [website]. Abbott Park, IL, Abbott Laboratories, 2000. [cited February 28, 2000]. [62p]

Eu commission approves Visudyne for the treatment of wet amd in the European Union [press release online]. Atlanta, GA, QLT Inc, July 28, 2000 [cited August 1, 2000] [7]. Available: http://www.qltinc.com.

Evans RA, Flynn J, Dunstan CR, George CR. Quantitative bone histology in end-stage renal failure. Prog Biochem Pharmacol 1980;17:236-241.

Evans RA, Flynn J, Dunstan CR, George CR, McDonnell GD. Bone metabolism in chronic renal failure. Miner Electrolyte Metab 1982 Apr;7(4):207-218.

Fabretti F, Calabrese V, Fornasari V, Poletti I. Subtotal parathyroidectomy for secondary hyperparathyroidism in chronic renal failure. J Laryngol Otol 1991 Jul;105(7):562-567.

Fajtova VT, Sayegh MH, Hickey N, Aliabadi P, Lazarus JM, LeBoff MS. Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 1995 Nov;57(5):329-335.

Falbo SE, Sundaram M, Ballal S, Domoto D, Martin K. Clinical significance of erosive azotemic osteodystrophy: A prospective masked study. Skeletal Radiol 1999 Feb;28(2):86-89.

Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 2000 Feb;57(2):684-690.

Farrington K, Varghese Z, Baillod RA, Fernando ON, Moorhead JF. Hypophosphataemia after parathyroidectomy in chronic renal failure. Br Med J (Clin Res Ed) 1982 Mar 20;284(6319):856-858.

Fassier F, St-Pierre M, Robitaille P. Renal osteodystrophy in children: correlation between aetiology of the renal disease and the frequency of bone and articular lesions. Int Orthop 1993;17(4):269-271.

Faugere MC, Arnala IO, Ritz E, Malluche HH. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med 1986 Jun;107(6):481-487.

Felsenfeld AJ, Gutman RA, Drezner M, Llach F. Hypophosphatemia in long-term renal transplant recipients: Effects on bone histology and 1,25-dihydroxycholecalciferol. Miner Electrolyte Metab 1986;12(5-6):333-341.

Felsenfeld AJ, Gutman RA, Llach F, Harrelson JM, Wells SA. Postparathyroidectomy hypocalcemia as an accurate indicator of preparathyroidectomy bone histology in the uremic patient. Miner Electrolyte Metab 1984;10(3):166-172.

Felsenfeld AJ, Harrelson JM, Gutman RA. A quantitative histomorphometric comparison of 40 micron thick Paragon sections with 5 micron thick Goldner sections in the study of undecalcified bone. Calcif Tissue Int 1982 May;34(3):232-238.

Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J. Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int 1993;13(4):296-301.

Feriani M, Kirchgessner J, La Greca G, Passlick- Deetjen J, Becker H, Bohler J, Brown CB, Buoncristiani U, Di Paolo N, Gahl GM, Gotloib L, Hylander B, Lameire N, Montenegro J, Pedersen FB, et al. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998;54(5):1731-1738.

Fernandez E, Fibla J, Betriu A, Piulats JM, Almirall J, Montoliu J. Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure. J Am Soc Nephrol 1997 Oct;8(10):1546-1552.

Fernandez-Reyes MJ, Auxiliadora Najo M, Robles P, Selgas R, Oliver J, Del Peso G, Garcia G, Jimenez C, Garcia-Gallego F. Mitral annular calcification in CAPD patients with a low degree of hyperparathyroidism. An analysis of other possible risk factors. Nephrol Dial Transplant 1995;10(11):2090-2095.

Ferraris JR, Pasqualini T, Legal S, Sorroche P, Galich AM, Pennisi P, Domene H, Jasper H. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrol 2000 Jul;14(7):682-688.

Finch T, Jacobs JK. Indications for parathyroidectomy in patients with chronic renal failure. Am Surg 1974 Jan;40(1):40-44.

Fischer ER, Harris DC. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 1993 Oct;40(4):216-220.

Fletcher S, Jones RG, Rayner HC, Harnden P, Hordon LD, Aaron JE, Oldroyd B, Brownjohn AM, Turney JH, Smith MA. Assessment of renal osteodystrophy in dialysis patients: Use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997;75(4):412-419.

Fletcher S, Kanagasundaram NS, Rayner HC, Irving HC, Fowler RC, Brownjohn AM, Turney JH, Will EJ, Davison AM. Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism. Nephrol Dial Transplant 1998 Dec;13(12):3111-3117.

Floege J. Beta-2-microglobulin derived amyloid and acquired cystic kidney disease, in Johnson RJ, Feehally J (eds): Principles of Nephrology. London, UK, Mosby International, 2000, pp 73.1-73.8.

Floege J. Diagnostic approaches to AB-amyloidosis. Blood Purif 1991;9(2):63-69.

Floege J, Burchert W, Brandis A, Gielow P, Nonnast-Daniel B, Spindler E, Hundeshagen H, Shaldon S, Koch KM. Imaging of dialysis-related amyloid (AB-amyloid) deposits with 131I-beta 2-microglobulin. Kidney Int 1990 Dec;38(6):1169-1176.

Floege J, Granolleras C, Merscher S, Eisenbach GM, Deschodt G, Colton CK, Shaldon S, Koch KM. Is the rise in plasma beta-2-microglobulin seen during hemodialysis meaningful? Nephron 1989;51(1):6-12.

Floege J, Schaeffer J, Koch KM. Diagnosis of beta-2-microglobulin associated amyloidosis by scintigraphy. Top Rev Rheum Disord 1994;61(9 Suppl):39S-42S.

Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000 Sep;54(3):218-226.

Foret M, Renversez JC, Meftahi H, Kuentz F, Milongo R, Hachache T, Vallin J, Dechelette E, Cordonnier D. How far can plasmatic levels of beta-2-microglobulin in hemodialysis be relied upon? Contrib Nephrol 1988;62:54-59.

Forget D, Caranhac G, Quillot MJ, Besnier MO. Compliance with very low protein diet and ketoanalogues in chronic renal failure. The French Multicentric Trial IRCCA. Contrib Nephrol 1990;81:79-86.

Forman MB, Virmani R, Robertson RM, Stone WJ. Mitral anular calcification in chronic renal failure. Chest 1984 Mar;85(3):367-371.

Fournier A, Fohrer P, Leflon P, Moriniere P, Tolani M, Lambrey G, Demontis R, Sebert JL, Van Devyver F, Debroe M. The desferrioxamine test predicts bone aluminium burden induced by A1(OH)3 in uraemic patients but not mild histological osteomalacia. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:371-376.

Franck H, Keck E, Issa S, Kruskemper HL, von Lilienfeld-Toal H. Serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin in chronic renal failure. Exp Clin Endocrinol 1988 May;91(2):202-206.

Franke S, Lehmann G, Abendroth K, Hein G, Stein G. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur J Med Res 1998 Feb 21;3(1-2):81-88.

Franklin SS, Gordon A, Kleeman CR, Maxwell MH. Use of a balanced low-protein diet in chronic renal failure. JAMA 1967 Nov 6;202(6):477-484.

Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000 Sep;36(3):550-561.

Freaney R, McKenna MJ, Casey O, Towers RP, Muldowney FP. Prospective application of a diagnostic index for metabolic bone disease. Ir Med J 1986 Apr;79(4):96-99.

Friberg O, Nurminen M, Korhonen K, Soininen E, Manttari T. Accuracy and precision of clinical estimation of leg length inequality and lumbar scoliosis: comparison of clinical and radiological measurements. Int Disabil Stud 1988;10(2):49-53.

Frohling PT, Kokot F, Schmicker R, Kaschube I, Lindenau K, Vetter K. Influence of keto acids on serum parathyroid hormone levels in patients with chronic renal failure. Clin Nephrol 1983 Oct;20(4):212-215.

Frohling PT, Kokot F, Vetter K, Hohmann WD, Werner G, Grossmann I, Schmicker R, Lindenau K. Treatment of renal osteodystrophy in advanced renal failure during predialysis time. Contrib Nephrol 1984;37:62-65.

Frohling PT, Schmicker R, Kokot F, Vetter K, Kaschube J, Gotz KH, Jacopian M, Lindenau K. Influence of phosphate restriction, keto-acids and vitamin D on the progression of chronic renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985;21:561-566.

Frohling PT, Schmicker R, Vetter K, Kaschube I, Gotz KH, Jacopian M, Klinkman H. Conservative treatment with ketoacid and amino acid supplemented low-protein diets in chronic renal failure. Am J Clin Nutr 1980 Jul;33(7):1667-1672.

Fujimoto Y, Obara T, Ito Y, Kodama T, Nishi T. Surgical treatment of secondary hyperparathyroidism in patients with chronic renal failure: Reevaluation of indications for parathyroidectomy. Endocrinol Jpn 1985 Dec;32(6):863-874.

Fujisaki T, Hida M, Hiraga S, Osamura RY. Cellular proliferation and secretion in secondary hyperparathyroidism during renal failure. Nephron 1997;77(1):68-75.

Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993 Sep;92(3):1436-1443.

Fuss M, De Backer M, Brauman J, Nijs-Dewolf N, Manderlier T, Brauman H, Corvilain J. Parathyroid hormone plasma level in untreated chronic renal failure and in hemodialyzed patients. Nephron 1976;17(2):144-154.

Gabay C, Ruedin P, Slosman D, Bonjour JP, Leski M, Rizzoli R. Bone mineral density in patients with end-stage renal failure. Am J Nephrol 1993;13(2):115-123.

Gadallah MF, Arora N, Torres C, Ramdeen G, Schaeffer-Pautz A, Moles K. Pulse oral versus pulse intraperitoneal calcitriol: A comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients. Adv Perit Dial 2000;16:303-307.

Gagne ER, Urena P, Leite-Silva S, Zingraff J, Chevalier A, Sarfati E, Dubost C, Drueke TB. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992 Oct;3(4):1008-1017.

Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992 Nov;42(5):1191-1198.

Gao H, Lew SQ, Bosch JP. Moderate metabolic acidosis and its effects on serum parameters in hemodialysis patients. Nephron 2000 Oct;86(2):135-138.

Gasparri G, Camandona M, Jeantet A, Nano M, Desimone M, Bronda M, Deipoli M. Results after 223 parathyroidectomies for secondary hyperparathyroidism. Acta Chir Austriaca 1996;28(Suppl 124):32-34.

Gaucher A, Kessler M, Netter P, Azoulay E, Pere P, Mur JM. Dialysis arthropathy: the effect of age [letter]. J Rheumatol 1988 Dec;15(12):1880-1881. [letter]

Gaylin DS, Held PJ, Port FK, Hunsicker LG, Wolfe RA, Kahan BD, Jones CA, Agodoa LY. The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA 1993 Feb 3;269(5):603-608.

Geis WP, Popovtzer MM, Corman JL, Halgrimson CG, Groth CG, Starzi TE. The diagnosis and treatment of hyperparathyroidism after renal homotransplantation. Surg Gynecol Obstet 1973 Dec;137(6):997-1010.

Gejyo F, Homma N, Maruyama H, Arakawa M. Beta 2-microglobulin-related amyloidosis in patients receiving chronic hemodialysis. Contrib Nephrol 1988;68:263-269.

Gejyo F, Homma N, Saito H, Arakawa M. Carpal tunnel syndrome and beta-2 microglobulin amyloidosis: Histological and biochemical aspects, in Gejyo F, Brancaccio D, Bardin T, (eds): Dialysis Amyloidosis. Milan, Italy, Wichtig Editore, 1989, pp 35-56.

Gejyo F, Homma N, Suzuki Y, Arakawa M. Serum levels of beta 2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis [letter]. N Engl J Med 1986 Feb 27;314(9):585-586. [letter]

Gentile MG, Manna GM, Ferrario L, D’Amico G. Preliminary experience on dietary management of chronic renal failure. Contrib Nephrol 1986;53:102-108.

Genuth SM, Sherwood LM, Vertes V, Leonards JR. Plasma parathormone, calcium and phosphorus in patients with renal osteodystrophy undergoing chronic hemodialysis. J Clin Endocrinol Metab 1970 Jan;30(1):15-23.

Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996 Dec;11(12):2430-2438.

Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Moriniere P, Garabedian M, Eastwood J, Fournier A. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 1999 Jun;55(6):2169-2177.

Ghods AJ, Arghani H, Ghadiri G. Serum erythropoietin levels after renal transplantation with various graft outcomes. Transplant Proc 1995 Oct;27(5):2577-2578.

Giangrande A, Cant A, Solbiati L, Ravetto C. Ultrasonically guided fine-needle alcohol injection as an adjunct to medical treatment in second hyperparathyroidism. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1984;21:895-901.

Giangrande A, Castiglioni A, Solbiati L, Allaria P. Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 1992;7(5):412-421.

Giovannetti S. The compliance with supplemented diet by chronic uremics and their nutritional status. Infusionsther Klin Ernahr 1987 Oct;14(Suppl 5):4-7.

Goggin MJ, Black DA, Wells CP, Collins RE, Coakley AJ, Nunan TO, Wolfe JH, Gaunt JI, Croft DN, Young AE. Thallium-201 and technetium-99m subtraction scanning of the parathyroid glands in patients with hyperparathyroidism due to renal osteodystrophy. Contrib Nephrol 1987;56:196-199.

Gldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997;77(1):37-43.

Goldstein DA, Malluche HH, Massry SG. Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients. Contrib Nephrol 1980;18:42-54.

Goldstein S, Winston E, Chung TJ, et al. Chronic arthropathy in long-term hemodialysis. Am J Med 1985;78(1):82-86.

Gonzalez T, Cruz A, Balsa A, Jimenez C, Selgas R, Miguel JL, Gijon J. Erosive azotemic osteoarthropathy of the hands in chronic ambulatory peritoneal dialysis and hemodialysis. Clin Exp Rheumatol 1997 Jul-Aug;15(4):367-371.

Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary artery calcification in young adults with end state renanl disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-1483.

Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994 Oct;46(4):1160-1166.

Gosling P, Robinson BH, Sammons HG. Changes in protein-bound calcium in the serum of haemodialysis patients. Clin Sci Mol Med Suppl 1975 Jun;48(6):521-528.

Graf H, Kovarik J, Stummvoll HK, Wolf A, Pinggera WF. Renal phosphate wasting after successful kidney transplantation: 1-alpha vitamin D therapy in patients with normal parathyroid gland activity. Nephron 1981;28(6):285-288.

Greene SV, Falciglia G, Rademacher R. Relationship between serum phosphorus levels and various outcome measures in adult hemodialysis patients. J Ren Nutr 1998 Apr;8(2):77-82.

Grekas DM, Ellis HA, Ward MK, Martin AM, Parkinson I, Kerr DN. Bone disease in long-term hemodialysis patients with low dialysate aluminium. Uremia Invest 1984;8(1):9-15.

Gretz N, Meisinger E, Strauch M. Influence of diet and underlying renal disease on the rate of progression of chronic renal failure. Infusionsther Klin Ernahr 1987;14(Suppl 5):21-25.

Grotz W, Mundinger A, Gugel B, Exner V, Reichelt A, Schollmeyer P. Missing impact of cyclosporine on osteoporosis in renal transplant recipients. Transplant Proc 1994 Oct;26(5):2652-2653.

Grotz W, Rump JA, Niessen A, Schmidt-Gayk H, Schollmeyer P. Treatment of bone pain after kidney transplantation. Transplant Proc 1998 Aug;30(5):2114-2116.

Grotz WH, Mundinger FA, Gugel B, Exner V, Kirste G, Schollmeyer PJ. Bone fracture and osteodensitometry with dual energy x-ray absorptiometry in kidney transplant recipients. Transplantation 1994;58(8):912-915.

Grotz WH, Mundinger FA, Rasenack J, Speidel L, Olschewski M, Exner VM, Schollmeyer PJ. Bone loss after kidney transplantation: A longitudinal study in 115 graft recipients. Nephrol Dial Transplant 1995;10(11):2096-2100.

Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, Olschewski M, Schollmeyer PJ. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998 Oct 27;66(8):1004-1008.

Growth failure in children with renal diseases. A clinical trial in pediatric nephrology: Growth Failure in Renal Diseases (GFRD) Study. J Pediatr 1990 Feb;116(2):S1-S62.

Gurudev KC, Pathak V, Prabhakar KS, Bhaskar S, Prakash KC, Prabhakaran, Mani MK. Short term study on relative merits of acetate and bicarbonate dialysis. J Assoc Physicians India 1991 Dec;39(12):921-924.

Gyarmati J, Locsey L, Gyarmati J Jr, Barnak G, Kakuk G, Vargha G. The value of roentgenological and serological investigations in the detection of bone alterations caused by chronic renal insufficiency. Radiol Diagn (Berl) 1979;20(5):738-478.

Haajanen J, Saarinen O, Kuhlback B, et al. Aseptic necrosis of the femoral head following renal transplantation. Scand J Urol Nephrol 1985;19(3):221-226.

Haajanen J, Saarinen O, Laasonen L, Kuhlback B, Edgren J, Slatis P. Steroid treatment and aseptic necrosis of the femoral head in renal transplant recipients. Transplant Proc 1984 Oct;16(5):1316-1319.

Hakim RM, Lazarus JM. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988 Mar;11(3):238-247.

Hakim RM, Pontzer MA, Tilton D, Lazarus JM, Gottlieb MN. Effects of acetate and bicarbonate dialysate in stable chronic dialysis patients. Kidney Int 1985 Sep;28(3):535-540.

Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF 3rd. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996 Mar;7(3):472-478.

Hamdy NA, Boletis J, Charlesworth D, Kanis JA, Brown CB. Low calcium dialysate increases the tolerance to vitamin D in peritoneal dialysis. Contrib Nephrol 1991;89:190-198.

Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995 Feb 11;310(6976):358-363.

Hamdy NA, Risteli J, Risteli L, Harris S, Beneton MN, Brown CB, Kanis JA. Serum type I procollagen peptide: A non-invasive index of bone formation in patients on haemodialysis? Nephrol Dial Transplant 1994;9(5):511-516.

Hampl H, Steinmuller T, Frohling P, Naoum C, Leder K, Stabell U, Schnoy N, Jehle PM. Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab 1999 May-Jun;25(3):161-170.

Hampl H, Steinmuller T, Stabell U, Klingenberg HJ, Schnoy N, Neuhaus P. Recurrent hyperparathyroidism after total parathyroidectomy and autotransplantation in patients with long-term hemodialysis. Miner Electrolyte Metab 1991;17(4):256-260.

Cooper H, Hedges LV (eds): The Handbook of Research Synthesis. New York, NY, Russell Sage Foundation, 1994. 573 p.

Hargrove GM, Pasieka JL, Hanley DA, Murphy MB. Short- and long-term outcome of total parathyroidectomy with immediate autografting versus subtotal parathyroidectomy in patients with end- stage renal disease. Am J Nephrol 1999;19(5):559-564.

Harrison JE, McNeill KG, Meema HE, Oreopoulos D, Rabinovich S, Fenton S, Wilson DR. Partial body calcium measurements on patients with renal failure. Metabolism 1977 Mar;26(3):255-265.

Hart W, Duursma SA, Visser WJ, Njio LK. The hydroxyproline content of plasma of patients with impaired renal function. Clin Nephrol 1975;4(3):104-108.

Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. Psychol Bull 1995 Jan;117(1):167-178.

Hauglustaine D, Waer M, Michielsen P, Goebels J, Vandeputte M. Haemodialysis membranes, serum beta 2-microglobulin, and dialysis amyloidosis [letter]. Lancet 1986 May 24;1(8491):1211-1212.

Hayes JF, Gross GF, Schuman ES. Surgical management of renal hyperparathyroidism in the dialysis patient. Am J Surg 1982 May;143(5):569-571.

Heaf J, Tvedegaard E, Kanstrup IL, Fogh-Andersen N. Bone loss after renal transplantation: Role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 2000 Oct;14(5):457-463.

Heaf JG, Podenphant J, Andersen JR. Bone aluminium deposition in maintenance dialysis patients treated with aluminium-free dialysate: Role of aluminium hydroxide consumption. Nephron 1986;42(3):210-216.

Hecking E, Andrzejewski L, Prellwitz W, Opferkuch W, Muller D, Port FK. A controlled study of supplementation with essential amino acids and alpha-keto acids in the conservative management of patients with chronic renal failure. Z Ernahrungswiss 1982 Dec;21(4):299-311.

Hedges LV, Olkin I. Statistical methods for meta-analysis. Boston, MA, Academic Press, Inc, 1985. 369 p.

Heerfordt J, Olgaard K, Madsen S, Vistisen L, Jensen H, Lookkegaard H, Brix E. Osteoscintigraphic changes in kidney-transplanted patients. Nephron 1978;21(2):86-94.

Heidland A, Kult J. Long-term effects of essential amino acids supplementation in patients on regular dialysis treatment. Clin Nephrol 1975 Jun;3(6):234-239.

Hellman P, Backman U, Danielson BG, Akerstrom G, Rastad J, Wide L, Ljunghall S. Values of intact serum parathyroid hormone in different stages of renal insufficiency. Scand J Urol Nephrol 1991;25(3):227-232.

Hely D, Fennell RS 3d, Petty W, Hudson T, Richard GA. Osteonecrosis of the femoral head and condyle in the post transplantation courses of children and adolescents. Int J Pediatr Nephrol 1982 Dec;3(4):297-303.

Hemmeloff Andersen KE, Bengsgaard Pedersen F, Horder M. An assessment of dialysis-associated osteodystrophy in long-term peritoneal dialysis. Nephron 1982;30(4):328-332.

Henderson RG, Russell RG, Earnshaw MJ, Ledingham JG, Oliver DO, Woods CG. Loss of metacarpal and iliac bone in chronic renal failure: influence of haemodialysis, parathyroid activity, type of renal disease, physical activity and heparin consumption. Clin Sci (Colch) 1979 Apr;56(4):317-324.

Henrich WL, Woodard TD, Meyer BD, Chappell TR, Rubin LJ. High sodium bicarbonate and acetate hemodialysis: double-blind crossover comparison of hemodynamic and ventilatory effects. Kidney Int 1983 Aug;24(2):240-245.

Henry JF, Denizot A, Audiffret J, France G. Results of reoperations for persistent or recurrent secondary hyperparathyroidism in hemodialysis patients. World J Surg 1990 May-Jun;14(3):303-306; discussion 307.

Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ. Aplastic osteodystrophy without aluminum: The role of ‘suppressed’ parathyroid function. Kidney Int 1993 Oct;44(4):860-866.

Hercz G, Salusky IB, Norris KC, Fine RN, Coburn JW. Aluminum removal by peritoneal dialysis: Intravenous vs. intraperitoneal deferoxamine. Kidney Int 1986 Dec;30(6):944-948.

Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E, Gonzalez-Posada JM, Felsenfeld AJ, Rodriguez M, Torres A. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994;9(5):517-523.

Herrmann P, Ritz E, Schmidt-Gayk H, Schafer I, Geyer J, Nonnast-Daniel B, Koch K-M, Weber U, Horl W, Haas-Worle A, Kuhn K, Bierther B, Schneider P. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial. Nephron 1994;67(1):48-53.

Herselman MG, Albertse EC, Lombard CJ, Swanepoel CR, Hough FS. Supplemented low-protein diets—Are they superior in chronic renal failure? S Afr Med J 1995 May;85(5):361-365.

Higgins RM, Richardson AJ, Ratcliffe PJ, Woods CG, Oliver DO, Morris PJ. Total parathyroidectomy alone or with autograft for renal hyperparathyroidism? Q J M 1991 Apr;79(288):323-332.

Hindie E, Urena P, Jeanguillaume C, Melliere D, Berthelot JM, Menoyo-Calonge V, Chiappini-Briffa D, Janin A, Galle P. Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet 1999 Jun 26;353(9171):2200-2204.

Hirata M, Katsumata K, Masaki T, Koike N, Endo K, Tsunemi K, Ohkawa H, Kurokawa K, Fukagawa M. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999 Dec;56(6):2040-2047.

Hodson EM, Evans RA, Dunstan CR, Hills E, Wong SY, Rosenberg AR, Roy LP. Treatment of childhood renal osteodystrophy with calcitriol or ergocalciferol. Clin Nephrol 1985 Oct;24(4):192-200.

Holgado R, Haire H, Ross D, Sprague S, Pahl M, Jara A, Martin-Malo A, Rodriguez M, lmaden Y, Felsenfeld AJ. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res 2000 May;15(5):927-935.

Holman AJ, Gardner GC, Richardson ML, Simkin PA. Quantitative magnetic resonance imaging predicts clinical outcome of core decompression for osteonecrosis of the femoral head. J Rheumatol 1995 Oct;22(10):1929-1933.

Homma N, Gejyo F, Kobayashi H, Saito H, Sakai S, Suzuki M, Hirasawa Y, Arakawa M. Cystic radiolucencies of carpal bones, distal radius and ulna as a marker for dialysis-associated amyloid osteoarthropathy. Nephron 1992;62(1):6-12.

Honda K, Hara M, Ogura Y, Nihei H, Mimura N. Beta 2-microglobulin amyloidosis in hemodialysis patients. An autopsy study of intervertebral disks and posterior longitudinal ligaments. Acta Pathol Jpn 1990 Nov;40(11):820-826.

Hosking DJ, Chamberlain MJ. Calcium balance in chronic renal failure. A study using in vivo neutron activation analysis. Q J M 1973 Jul;42(167):467-479.

Hosokawa S, Yoshida O. Removal of silicon, aluminum and beta 2-microglobulin in chronic haemodialysis patients. Int Urol Nephrol 1991;23(3):281-284.

Howard RJ, Pfaff WW. Parathyroidectomy in patients with chronic renal failure. Am J Surg 1998 Apr;175(4):302-304.

Hulter HN, Peterson JC. Acid-base homeostasis during chronic PTH excess in humans. Kidney Int 1985 Aug;28(2):187-192.

Huraib S, Souqqiyeh MZ, Aswad S, al-Swailem AR. Pattern of renal osteodystrophy in haemodialysis patients in Saudi Arabia. Nephrol Dial Transplant 1993;8(7):603-608.

Hurst NP, van den Berg R, Disney A, Alcock M, Albertyn L, Green M, Pascoe V. ‘Dialysis related arthropathy’: A survey of 95 patients receiving chronic haemodialysis with special reference to beta 2 microglobulin related amyloidosis. Ann Rheum Dis 1989 May;48(5):409-420.

Hutchison AJ, Freemont AJ, Boulton HF, Gokal R. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992;7(12):1219-1225.

Hutchison AJ, Freemont AJ, Lumb GA, Gokal R. Renal osteodystrophy in CAPD. Adv Perit Dial 1991;7:237-239.

Hutchison AJ, Merchant M, Boulton HF, Hinchcliffe R, Gokal R. Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/L calcium, 0.25 mmol/L magnesium dialysis fluid. Perit Dial Int 1993;13(3):219-223.

Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, Gokal R. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993 Nov;44(5):1071-1077.

Hutchison AJ, Whitehouse RW, Freemont AJ, Adams JE, Mawer EB, Gokal R. Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 1994;14(1):19-29.

Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Weil R 3d. Calcification in end-stage kidneys. Am J Med 1981 Jul;71(1):33-37.

Ibels LS, Alfrey AC, Huffer WE, Weil R 3d. Aseptic necrosis of bone following renal transplantation: Experience in 194 transplant recipients and review of the literature. Medicine (Baltimore) 1978 Jan;57(1):25-45.

Ihle BU, Becker GJ, Whitworth JA, Charlwood RA, Kincaid-Smith PS. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 1989 Dec 28;321(26):1773-1777.

Indridason OS, Pieper CF, Quarles LD. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. J Clin Endocrinol Metab 1998 Nov;83(11):3860-3866.

Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000 JAN;57(1):282-292.

Ingham JP, Stewart JH, Posen S. Quantitative skeletal histology in untreated end-stage renal failure. Br Med J 1973 Jun 30;2(869):745-748.

Ishibashi M, Nishida H, Hiromatsu Y, Kojima K, Tabuchi E, Hayabuchi N. Comparison of technetium-99m-MIBI, technetium-99m-tetrofosmin, ultrasound and MRI for localization of abnormal parathyroid glands . J Nucl Med 1998 Feb;39(2):320-324.

Ishibashi M, Nishida H, Okuda S, Suekane S, Hayabuchi N. Localization of parathyroid glands in hemodialysis patients using Tc-99m sestamibi imaging. Nephron 1998;78(1):48-53.

Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999 Mar;55(3):1019-1027.

Ito M, Ito M, Hayashi K, Noguchi M, Kitamori H. Evaluation of spinal bone changes in patients with chronic renal failure by CT and MR imaging with pathologic correlation. Acta Radiol 1994 May;35(3):291-295.

Ittel TH, Schafer C, Schmitt H, Gladziwa U, Sieberth HG. Calcium carbonate as a phosphate binder in dialysis patients: Evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia. Klin Wochenschr 1991 Jan 22;69(2):59-67.

Coburn J. (UCLA Medical Center). Personal communication. December 22, 2000.

Jacobs JW, Blaauw AA, Dijkmans BA, Van Riel PL, Bijlsma JW. Pharmacotherapy of patients with (early) rheumatoid arthritis. Ned Tijdschr Geneeskd 2000;144(5):211-216.

Jadoul M, Garbar C, Noel H, Sennesael J, Vanholder R, Bernaert P, Rorive G, Hanique G, van Ypersele de Strihou C. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 1997 Jun;51(6):1928-1932.

Jadoul M, Malghem J, Vande Berg B, van Ypersele de Strihou C. Ultrasonographic detection of thickened joint capsules and tendons as marker of dialysis-related amyloidosis: A cross-sectional and longitudinal study. Nephrol Dial Transplant 1993;8(10):1104-1109.

Janssen MJ, van Boven WP. Efficacy of low-dose desferrioxamine for the estimation of aluminium overload in haemodialysis patients. Pharm World Sci 1996 Oct;18(5):187-191.

Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996 Feb;45(2):111-119.

Jarava C, Armas JR, Salgueira M, Palma A. Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Nephrol Dial Transplant 1996;11 Suppl 3:43-46.

Jeanguillaume C, Urena P, Hindie E, Prieur P, Petrover M, Menoyo-Calonge V, Janin A, Chiappini-Briffa D, Melliere D, Boulahdour H, Galle P. Secondary hyperparathyroidism: Detection with I-123-Tc-99m-Sestamibi subtraction scintigraphy versus US. Radiology 1998 Apr;207(1):207-213.

Jenkins DA, Gouldesbrough D, Smith GD, Cowie JF, Winney RJ. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Nephrol Dial Transplant 1989;4(1):51-56.

Jespersen B, Jensen JD, Nielsen HK, Lauridsen IN, Andersen MJ, Poulsen JH, Gammelgaard B, Pedersen EB. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients. Nephrol Dial Transplant 1991;6(2):98-104.

Joffe P, Heaf JG, Jensen C. Can bone histomorphometry be predicted by clinical assessment and noninvasive techniques in peritoneal dialysis? Miner Electrolyte Metab 1996;22(4):224-233.

Johnson DW, Rigby RJ, McIntyre HD, Brown A, Freeman J. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients. Nephrol Dial Transplant 1996 Jan;11(1):88-93.

Johnson WJ, McCarthy JT, van Heerden JA, Sterioff S, Grant CS, Kao PC. Results of subtotal parathyroidectomy in hemodialysis patients. Am J Med 1988 Jan;84(1):23-32.

Jorge C, Gil C, Possante M, Catarino MC, Cruz A, Andrade R, Teixeira R, Santos N, Ferreira A. Use of a desferrioxamine ‘microdose’ to chelate aluminum in hemodialysis patients. Clin Nephrol 1999;52(5):335-336.

Jureidini KF, Hogg RJ, van Renen MJ, Southwood TR, Henning PH, Cobiac L, Daniels L, Harris S. Evaluation of long-term aggressive dietary management of chronic renal failure in children. Pediatr Nephrol 1990 Jan;4(1):1-10.

Juttmann JR, Birkenhager-Frenkel DH, Visser TJ, van Krimpen C, Birkenhager JC. Follow-up of long-term treatment of predialysis renal bone disease with 1-alpha-hydroxy-derivatives of vitamin D. J Steroid Biochem 1983 Jul;19(1B):511-516.

Juttmann JR, Hagenouw-Taal JC, Lameyer LD, Ruis AM, Birkenhager JC. A longitudinal study of bone-mineral content and intestinal calcium absorption in patients with chronic renal failure. Metabolism 1979 Nov;28(11):1114-1121.

Kachel HG, Altmeyer P, Baldamus CA, Koch KM. Deposition of an amyloid-like substance as a possible complication of regular dialysis treatment. Contrib Nephrol 1983;36:127-132.

Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H, Kurokawa K, Saito A. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999 Jun;33(6):1091-1099.

Kakuta T, Kunimatsu K, Tadaki F, Fujisaki T, Noguchi M, Abe Y, Sakai H, Kurokawa K, Saito A. Long-term prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients. Biomed Pharmacother 2000;54(Suppl 1):60S-65S.

Kampf D, Fischer HC, Kessel M. Efficacy of an unselected protein diet (25 g) with minor oral supply of essential amino acids and keto analogues compared with a selective protein diet (40 g) in chronic renal failure. Am J Clin Nutr 1980 Jul;33(7):1673-1677.

Kamphuis AGA, Geerlings W, Hazenberg BPC, Thijn CJP. Annual evaluation of hip joints and hands for radiographic signs of AßM-amyloidosis in long-term hemodialysis patients. Skeletal Radiol 1994;23(6):421-427.

Kancir CB, Wanscher M, Petersen PH. Ionized and total calcium variations induced by haemodialysis. Nephron 1988;48(4):319-323.

Kanis JA, Earnshaw M, Henderson RG, Heynen G, Ledingham JG, Naik RB, Oliver DO, Russell RG, Smith R, Wilkinson RH, Woods CG. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease. Clin Endocrinol (Oxf) 1977 Dec;7 Suppl:45s-50s.

Karantanas AH, Kalef-Ezra JA, Sferopoulos G, Siamopoulos KC. Quantitative computed tomography for spinal bone mineral measurements in chronic renal failure. Br J Radiol 1996 Feb;69(818):132-136.

Karkoszka H, Chudek J, Strzelczyk P, Wiecek A, Schmidt-Gayk H, Ritz E, Kokot F. Does the vitamin D receptor genotype predict bone mineral loss in haemodialysed patients? Nephrol Dial Transplant 1998 Aug;13(8):2077-2080.

Karsenty G, Vigneron N, Jorgetti V, Fauchet M, Zingraff J, Drueke T, Cournot-Witmer G. Value of the 99mTc-methylene diphosphonate bone scan in renal osteodystrophy. Kidney Int 1986 May;29(5):1058-1065.

Kasiske BL, London W, Ellison MD. Race and socioeconomic factors influencing early placement on the kidney transplant waiting list. J Am Soc Nephrol 1998 Nov;9(11):2142-2147.

Katagiri M, Fukunaga M, Ohtawa T, Harada T, Henry JF. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: Evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I p(TRUNC). World J Surg 1996;20(7):753-757.

Kates DM, Sherrard DJ, Andress DL. Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. Am J Kidney Dis 1997 Dec;30(6):809-813.

Katz AD, Kaplan L. Parathyroidectomy for hyperplasia in renal disease. Arch Surg 1973 Jul;107(1):51-55.

Katz AI, Hampers CL, Merrill JP. Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Analysis of 195 patients, with observations on the effects of chronic dialysis, kidney transplantation and subtotal parathyroidectomy. Medicine (Baltimore) 1969 Sep;48(5):333-374.

Katz AI, Hampers CL, Wilson RE, Bernstein DS, Wachman A, Merrill JP. The place of subtotal parathyroidectomy in the management of patients with chronic renal failure. Trans Am Soc Artif Intern Organs 1968;14:376-384.

Kausz AT, Antonsen JE, Hercz G, Pei Y, Weiss NS, Emerson S, Sherrard DJ. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 1999 Oct;34(4):688-693.

Kawanishi H, Tsuchiya T, Namba S, Takahashi N, Toyota T, Fukuma K, Kawai T. Clinical application of low calcium peritoneal dialysate. ASAIO Trans 1991 Jul-Sep;37(3):M404-M406.

Kay J, Benson CB, Lester S, Corson JM, Pinkus GS, Lazarus JM, Owen WF Jr. Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. Arthritis Rheum 1992 Aug;35(8):926-932.

Kaye M. Long-term studies using a calcium-free dialysate. Clin Nephrol 1993;40(4):221-224.

Kaye M, D’Amour P, Henderson J. Elective total parathyroidectomy without autotransplant in end-stage renal disease. Kidney Int 1989 Jun;35(6):1390-1399.

Kaye M, Henderson J. Direct functional assessment of human osteoblasts by radioautography: methodology and application in end stage renal disease. Clin Invest Med 1988 Jun;11(3):224-233.

Kaye M, Rosenthall L, Hill RO, Tabah RJ. Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol 1993 Apr;39(4):192-197.

Kaye M, Silverman M. Calcium metabolism in chronic renal failure. J Lab Clin Med 1965 Oct;66(4):535-548.

Kaye M, Turner M, Ardila M, Wiegmann T, Hodsman A. Aluminum and phosphate. Kidney Int Suppl 1988 Mar;24:S172-S174.

Kerby JD, Rue LW, Blair H, Hudson S, Sellers MT, Diethelm AG. Operative treatment of tertiary hyperparathyroidism: a single-center experience. Ann Surg 1998 Jun;227(6):878-886.

Kessler M, Netter P, Azoulay E, Mayeux D, Pere P, Gaucher A. Dialysis-associated arthropathy: A multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. Br J Rheumatol 1992 Mar;31(3):157-162.

Kessler M, Netter P, Gaucher A. Dialysis membranes and dialysis-associated arthropathy. Rev Rhum Engl Ed 1994;61(9 Suppl):71S-74S.

Kessler M, Netter P, Maheut H, Wolf C, Prenat E, Huu TC, Gaucher A. Highly permeable and biocompatible membranes and prevalence of dialysis-associated arthropathy [letter]. Lancet 1991 May 4;337(8749):1092-1093.

Khajehdehi P, Ali M, Al-Gebory F, Henry G, Bastani B. The effects of parathyroidectomy on nutritional and biochemical status of hemodialysis patients with severe secondary hyperparathyroidism. J Ren Nutr 1999 Oct;9(4):186-191.

Kim HC, Cheigh JS, David DS, Stubenbord W, Sullivan J, Rubin AL, Stenzel KH. Long term results of subtotal parathyroidectomy in patients with end- stage renal disease. Am Surg 1994 Sep;60(9):641-649.

Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl 1998 Jul;71:S238-S241.

Kinnaert P, Nagy N, Decoster-Gervy C, De Pauw L, Salmon I, Vereerstraeten P. Persistent hyperparathyroidism requiring surgical treatment after kidney transplantation. World J Surg 2000 Nov;24(11):1391-1395.

Kinnaert P, Salmon I, Decoster-Gervy C, Vienne A, De Pauw L, Hooghe L, Tielemans C. Long-term results of subcutaneous parathyroid grafts in uremic patients. Arch Surg 2000 Feb;135(2):186-190.

Kinnaert P, Tielemans C, Dhaene M, Decoster-Gervy C. Evaluation of surgical treatment of renal hyperparathyroidism by measuring intact parathormone blood levels on first postoperative day. World J Surg 1998 Jul;22(7):695-699.

Kist-van Holthe tot Echten JE, Nauta J, Boerma GJ, Hop WC, Noordzij CM, Wolff ED. Protein restriction affects fat intake and serum lipids in children with chronic renal failure. Miner Electrolyte Metab 1992;18(2-5):207-211.

Kist-van Holthe tot Echten JE, Nauta J, Hop WC, de Jong MC, Reitsma-Bierens WC, Ploos van Amstel SL, van Acker KJ, Noordzij CM, Wolff ED. Protein restriction in chronic renal failure. Arch Dis Child 1993 Mar;68(3):371-375.

Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994 Mar 31;330(13):877-884.

Klaus G, Mehls O, Hinderer J, Ritz E. Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? [letter]. Lancet 1991 Mar 30;337(8744):800-801.

Klinkmann H, Buscaroli A, Stefoni S. ß-Microglobulin and low-flux synthetic dialyzers. Artif Organs 1998;22(7):585-590.

Kobayashi S, Miyakawa M, Kasuga Y, Yokozawa T, Senga O, Sugenoya A, Iida F. Parathyroid imaging: Comparison of 201Tl-99mTc subtraction scintigraphy, computed tomography and ultrasonography. Jpn J Surg 1987 Jan;17(1):9-13.

Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997 Oct;52(4):1096-1101.

Kohlmeier M, Saupe J, Schaefer K, Asmus G. Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype. Calcif Tissue Int 1998 Mar;62(3):278-281.

Koonsman M, Hughes K, Dickerman R, Brinker K, Dunn E. Parathyroidectomy in chronic renal failure. Am J Surg 1994 Dec;168(6):631-634; discussion 634-635.

Kopple JD, Berg R, Houser H, Steinman TI, Teschan P. Nutritional status of patients with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989 Nov;27:S184-S194.

Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR, Zimmer GS. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 1997 Sep;52(3):778-791.

Korzets Z, Magen H, Kraus L, Bernheim J, Bernheim J. Total parathyroidectomy with autotransplantation in haemodialysed patients with secondary hyperparathyroidism—Should it be abandoned? Nephrol Dial Transplant 1987;2(5):341-346.

Kostakis A, Vaiopoulos G, Kostantopoulos K, Zavos G, Bocos I, Sgouromalis S. Parathyroidectomy in the treatment of secondary hyperparathyroidism in chronic renal failure. Int Surg 1997 Jan-Mar;82(1):85-86.

Kraut JA, Shinaberger JH, Singer FR, Sherrard DJ, Saxton J, Miller JH, Kurokawa K, Coburn JW. Parathyroid gland responsiveness to acute hypocalcemia in dialysis osteomalacia. Kidney Int 1983 May;23(5):725-730.

Kriegshauser JC, Swee RG, McCarthy JT, Hauser MF. Aluminum toxicity in patients undergoing dialysis: Radiographic findings and prediction of bone biopsy results. Radiology 1987;164(2):399-403.

Kuchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996;16(6):484-488.

Kuhlback B, Sivula A, Kock B, Kahri A, Wallenius M. Secondary hyperparathyroidism and parathyroidectomy in terminal chronic renal failure. Scand J Urol Nephrol Suppl 1977;(42):140-143.

Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998 Jan;53(1):205-211.

Kuizon BD, Salusky IB. Intermittent calcitriol therapy and growth in children with chronic renal failure. Miner Electrolyte Metab 1998;24(4):290-295.

Kuntz D, Maziere B, Sebert JL, Moriniere P, Meunier PJ, Duquesnoy N, Fournier A. Advantage of hand bone calcium content measurement by local neutron activation analysis for following up hemodialysis patients. Nephron 1983;34(4):228-233.

Kurer MH, Baillod RA, Madgwick JC. Musculoskeletal manifestations of amyloidosis. A review of 83 patients on haemodialysis for at least 10 years. J Bone Joint Surg Br 1991 Mar;73(2):271-276.

Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994 Sep;46(3):855-861.

Kusec V, Smalcelj R, Cvijetic S, Rozman B, Skreb F. Determinants of reduced bone mineral density and increased bone turnover after kidney transplantation: cross-sectional study. Croat Med J 2000 Dec 15;41(4):396-400.

Kuzela DC, Huffer WE, Conger JD, Winter SD, Hammond WS. Soft tissue calcification in chronic dialysis patients. Am J Pathol 1977 Feb;86(2):403-424.

La Greca G, Feriani M, Bragantini L, et al. Effects of acetate and bicarbonate dialysate on vascular stability: A prospective multicenter study. Int J Artif Organs 1987;10(3):157-162.

Lamperi S, Vagge R. Effects of 1-alpha OH D3 therapy in uremic patients in conservative or dialytic treatment. Int J Artif Organs 1979 Sep;2(5):243-247.

Landmann J, Renner N, Gachter A, Thiel G, Harder F. Cyclosporin A and osteonecrosis of the femoral head. J Bone Joint Surg Am 1987 Oct;69(8):1226-1228.

Langman CB, Mazur AT, Baron R, Norman ME. 25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity. J Pediatr 1982 May;100(5):815-820.

Lanteri M, Ptasznik R, Constable L, Dawborn JK. Ultrasound changes in the wrist and hand in hemodialysis patients. Clin Nephrol 1997 Dec;48(6):375-380.

Laurent G, Calemard E, Charra B. Dialysis related amyloidosis. Kidney Int Suppl 1988 Mar;24:S32-S34.

Lausten GS, Lemser T, Jensen PK, Egfjord M. Necrosis of the femoral head after kidney transplantation. Clin Transplant 1998 Dec;12(6):572-574.

Lavaud S, Troupance O, Roujoulch H, Fakir M, Melin JP, Chanard J. Carpal tunnel syndrome in hemodialysis patients: effect of dialysis strategy, in Man, Mion, Henderson (eds). Blood Purification in Perspective: New Insights and Future Trends. Cleveland, OH, ISAO Press, 1987, pp 125-8.

Ledermann SE, Johnson A, Dillon MJ, Trompeter RS, Barratt TM. Serum intact parathyroid hormone and ionised calcium concentration in children with renal insufficiency. Pediatr Nephrol 1994 Oct;8(5):561-565.

Lee WT, Padayachi K, Collins JF, Cundy T. A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. J Am Soc Nephrol 1994 Dec;5(6):1344-1348.

Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989 Dec;36(6):1112-1118.

Lerner A, Kramer M, Goldstein S, Caruana R, Epstein S, Raja R. Calcium carbonate. A better phosphate binder than aluminum hydroxide. ASAIO Trans 1986 Jul-Sep;32(1):315-318.

Letteri JM, Ellis KJ, Orofino DP, Ruggieri S, Asad SN, Cohn SH. Altered calcium metabolism in chronic renal failure. Kidney Int 1974 Jul;6(1):45-54.

Levey AS, Adler S, Caggiula AW, England BK, Greene T, Hunsicker LG, Kusek JW, Rogers NL, Teschan PE. Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study. Am J Kidney Dis 1996;27(5):652-663.

Levin KE, Gooding GA, Okerlund M, Higgins CB, Norman D, Newton TH, Duh QY, Arnaud CD, Siperstein AE, Zeng QH. Localizing studies in patients with persistent or recurrent hyperparathyroidism. Surgery 1987 Dec;102(6):917-925.

Levitt MD, Vivian AB, Saker BM. Parathyroidectomy in chronic renal failure. Aust N Z J Surg 1986 Mar;56(3):233-239.

Lewis EJ, Tolchin N, Roberts JL. Estimation of the metabolic conversion of acetate to bicarbonate during hemodialysis. Kidney Int Suppl 1980 Sep;Suppl 10:S51-S55.

Lin YF, Shieh SD, Diang LK, Lin SH, Chyr SH, Li BL, Lu KC. Influence of rapid correction of metabolic acidosis on serum osteocalcin level in chronic renal failure. ASAIO J 1994 Jul-Sep;40(3):M440-M444.

Lindberg JS, Copley JB, Koenig KG, Cushner HM. Effect of citrate on serum aluminum concentrations in hemodialysis patients: A prospective study. South Med J 1993 Dec;86(12):1385-1388.

Linde K, Scholz M, Ramirez G, Clausius N, Melchart D, Jonas WB. Impact of study quality on outcome in placebo-controlled trials of homeopathy. J Clin Epidemiol 1999 Jul;52(7):631-636.

Lindenau K, Kokot F, Vetter K, Hohmann WD, Werner G, Buder R, Grossmann I, Frohling PT. How to prevent renal osteodystrophy. Contrib Nephrol 1984;37:66-69.

Lindergard B. Changes in bone mineral content evaluated by photon absorptiometry before the start of active uremia treatment. Clin Nephrol 1981 Sep;16(3):126-130.

Lindergard B, Johnell O, Nilsson BE, Wiklund PE. Studies of bone morphology, bone densitometry and laboratory data in patients on maintenance hemodialysis treatment. Nephron 1985;39(2):122-129.

Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 1994;20(3):97-102.

Liou HH, Chiang SS, Tsai SC, Chang CC, Wu SC, Shieh SD, Huang TP. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Chung Hua I Hsueh Tsa Chih (Taipei) 1994 Jun;53(6):319-324.

Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: A new meta-analytic method. Med Decis Making 1993 Oct-Dec;13(4):313-321.

Ljunghall S, Althoff P, Fellstrom B, Marjanovic B, Nisell J, Weiss L, Wide L. Effects on serum parathyroid hormone of intravenous treatment with alfacalcidol in patients on chronic hemodialysis. Nephron 1990;55(4):380-385.

Ljutic D, Cameron JS, Ogg CS,